Anti-Rh(D) Immunoglobulin Injection

A blood fraction containing antibodies against Rh(D) antigen, administered prophylactically to prevent hemolytic disease in newborns. Classified in HTS 3002.12.0090 as an antiserum derived from human plasma via biotechnological processes for therapeutic use. It targets specific immunological responses rather than general blood components.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
๐Ÿ‡จ๐Ÿ‡ณChinaFreeโ€”Free
๐Ÿ‡ฒ๐Ÿ‡ฝMexicoFreeโ€”Free
๐Ÿ‡จ๐Ÿ‡ฆCanadaFreeโ€”Free
๐Ÿ‡ฉ๐Ÿ‡ชGermanyFreeโ€”Free
๐Ÿ‡ฏ๐Ÿ‡ตJapanFreeโ€”Free

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002Same rate: Free

If derived from animal blood

Animal-sourced antisera like equine anti-Rh fall under 3002.11 for non-human blood fractions.

3006.92.00.00Higher: 10% vs Free

If packaged in measured doses for retail

Pre-filled syringes of immunological products for direct administration may shift to Chapter 30 heading 3006 for pharmaceutical preparations.

3822.19.00Higher: 10% vs Free

If for diagnostic lab reagents only

If solely for in-vitro diagnostic testing and not therapeutic, it classifies as diagnostic reagents in Chapter 38.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

โ€ข Include lot-specific Rh antibody titer reports and sterility certificates to comply with biologics import regs

โ€ข Use validated shipping containers for temperature control; declare as pharmaceutical to avoid inspection delays

Related Products under HTS 3002.12.00.90

Human Immunoglobulin G (IgG) Concentrate

A purified fraction of human blood plasma containing high levels of Immunoglobulin G antibodies, used therapeutically to treat primary immunodeficiencies and autoimmune disorders. It falls under HTS 3002.12.0090 as an immunological product derived from blood fractions, prepared for therapeutic use via biotechnological purification processes. This excludes simple blood products without specific immunological modification.

Cytomegalovirus (CMV) Hyperimmune Globulin

Hyperimmune plasma fraction enriched with CMV-specific antibodies for preventing CMV infection in transplant patients. Falls under HTS 3002.12.0090 as an other blood fraction/antisera prepared for prophylactic use through plasma fractionation. It meets the definition of immunological products from human blood.

Botulinum Toxin Type A Immune Globulin

Antitoxin derived from human plasma fractions containing antibodies against botulinum toxin, used to treat infant botulism. Classified in HTS 3002.12.0090 as an immunological blood fraction for therapeutic neutralization of toxins. It involves biotech purification of specific antisera.

Tetanus Immune Globulin (TIG)

Human blood fraction providing passive immunity against tetanus toxin for wound management. Under HTS 3002.12.0090 as other blood fraction antisera prepared for therapeutic use. Involves hyperimmunization and plasma fractionation.

Hepatitis B Immune Globulin (HBIG)

Plasma-derived antibodies specific to hepatitis B surface antigen for post-exposure prophylaxis in high-risk cases. Classifies in HTS 3002.12.0090 as an immunological blood fraction/antiserum. Biotechnological pooling and purification ensure specificity.

Varicella Zoster Immune Globulin (VZIG)

Human immune globulin enriched for varicella-zoster virus antibodies to prevent severe chickenpox in immunocompromised patients. HTS 3002.12.0090 for other specific antisera from blood fractions. Prepared via donor plasmapheresis and affinity purification.